Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma

[1]  S. Carr,et al.  Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.

[2]  Christopher J. Ott,et al.  The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.

[3]  A. Keith Stewart,et al.  How Thalidomide Works Against Cancer , 2014, Science.

[4]  R. Chopra,et al.  Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity , 2013, British journal of haematology.

[5]  M. Amiot,et al.  Cereblon expression in multiple myeloma: not ready for prime time , 2013, British journal of haematology.

[6]  H. Ludwig,et al.  Cereblon expression in multiple myeloma: not ready for prime time – Response to Lodé et al , 2013, British journal of haematology.

[7]  U. Jäger,et al.  High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone , 2013, British journal of haematology.

[8]  Winnie S. Liang,et al.  Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease , 2013, British journal of haematology.

[9]  D. Hose,et al.  High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. , 2013, Blood.

[10]  A. Belch,et al.  High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide , 2012 .

[11]  P. L. Bergsagel,et al.  Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. , 2011, Blood.

[12]  G. Morgan,et al.  Guidelines for the diagnosis and management of multiple myeloma 2011 , 2011, British journal of haematology.

[13]  M. Dimopoulos,et al.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.

[14]  H. Handa,et al.  Teratogenic effects of thalidomide: molecular mechanisms , 2011, Cellular and Molecular Life Sciences.

[15]  Michael L. Wang,et al.  Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide , 2010, The Journal of Biological Chemistry.

[16]  M. Baccarani,et al.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study , 2010, The Lancet.

[17]  K. Kang,et al.  Induction of cereblon by NF-E2-related factor 2 in neuroblastoma cells exposed to hypoxia-reoxygenation. , 2010, Biochemical and biophysical research communications.

[18]  Toshihiko Ogura,et al.  Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.

[19]  Bin Jiang,et al.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.

[20]  Nie Xiaohua,et al.  Primary function analysis of human mental retardation related gene CRBN , 2008, Molecular Biology Reports.

[21]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[22]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[23]  R. Walker,et al.  Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment I , 2006, Histopathology.

[24]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[25]  Chul-Seung Park,et al.  Identification and functional characterization of cereblon as a binding protein for large‐conductance calcium‐activated potassium channel in rat brain , 2005, Journal of neurochemistry.

[26]  M. Yao,et al.  Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  J. Higgins,et al.  A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation , 2004, Neurology.

[28]  S. Hsu,et al.  Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system. , 2004, The American journal of pathology.

[29]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[31]  B. Barlogie,et al.  The clinical significance of cereblon expression in multiple myeloma. , 2014, Leukemia research.

[32]  M. Frech,et al.  Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding , 2012, Leukemia.

[33]  A. Stewart,et al.  What is the functional role of the thalidomide binding protein cereblon? , 2011, International journal of biochemistry and molecular biology.

[34]  M. Smyth,et al.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma , 2010, Leukemia.

[35]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.